Liposarcoma Multimodality Management and Future Targeted Therapies

被引:110
|
作者
Crago, Aimee M. [1 ,2 ,3 ]
Dickson, Mark A. [1 ,4 ,5 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Sarcoma Dis Management Team, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Surg, Gastr & Mixed Tumor Serv, 1275 York Ave,H1220, New York, NY 10065 USA
[3] Weill Cornell Med Coll, Dept Surg, 1300 York Ave, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med, Sarcoma Oncol Serv, 300 East 66th St, New York, NY 10065 USA
[5] Weill Cornell Med Coll, Dept Med, 1300 York Ave, New York, NY 10065 USA
关键词
Sarcoma; Liposarcoma; Myxoid liposarcoma; Pleomorphic liposarcoma; CDK4; MDM2; FUS-CHOP; Trabectedin; SOFT-TISSUE SARCOMA; RANDOMIZED PHASE-II; DEDIFFERENTIATED LIPOSARCOMA; MYXOID LIPOSARCOMA; LIPOMATOUS TUMORS; CELL LIPOSARCOMA; MDM2; PROMOTES; EXTREMITY; SUBTYPE; CHEMOTHERAPY;
D O I
10.1016/j.soc.2016.05.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There are 3 biologic groups of liposarcoma: well-differentiated and dedifferentiated liposarcoma, myxoid/round cell liposarcoma, and pleomorphic liposarcoma. In all 3 groups, complete surgical resection is central in treatment aimed at cure and is based on grade. Radiation can reduce risk of local recurrence in high-grade lesions or minimize surgical morbidity in the myxoid/round cell liposarcoma group. The groups differ in chemosensitivity, so adjuvant chemotherapy is selectively used in histologies with metastatic potential but not in the resistant subtype dedifferentiated liposarcoma. Improved understanding of the genetic aberrations that lead to liposarcoma initiation is allowing for the rapid development of targeted therapies for liposarcoma.
引用
收藏
页码:761 / +
页数:14
相关论文
共 50 条
  • [21] Emerging Targeted and Immune-Based Therapies in Sarcoma
    Pollack, Seth M.
    Ingham, Matthew
    Spraker, Matthew B.
    Schwartz, Gary K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (02) : 125 - +
  • [22] Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
    Perez-Herrero, Edgar
    Fernandez-Medarde, Alberto
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 93 : 52 - 79
  • [23] Diagnosis, Management, and Outcome of Patients with Dedifferentiated Liposarcoma Systemic Metastasis
    Markus P. Ghadimi
    Tariq Al-Zaid
    John Madewell
    Tingsheng Peng
    Chiara Colombo
    Aviad Hoffman
    Chad J. Creighton
    Yiqun Zhang
    Anna Zhang
    Alexander J. Lazar
    Raphael E. Pollock
    Dina Lev
    Annals of Surgical Oncology, 2011, 18 : 3762 - 3770
  • [24] Management and Prevention of Recurrent Paratesticular Liposarcoma
    Song, Chun Hoong
    Chai, Feng Yih
    Saukani, Mohd Faizal Mohamad
    Singh, Harbahajan
    Jiffre, Din
    MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2013, 20 (04): : 95 - 97
  • [25] Potential targeted therapeutic approaches in liposarcoma
    Kanojia, Deepika
    Garg, Manoj
    Koeffler, H. Phillip
    AGING-US, 2016, 8 (04): : 569 - 570
  • [26] Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies
    Walter, Sebastian Gottfried
    Knoell, Peter
    Eysel, Peer
    Quaas, Alexander
    Gaisendrees, Christopher
    Nissler, Robert
    Hieggelke, Lena
    CANCERS, 2023, 15 (09)
  • [27] Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma
    Biczo, Adam
    Sahgal, Arjun
    Verlaan, Jorrit-Jan
    Shreyaskumar, Patel
    Szoverfi, Zsolt
    Schultheiss, Markus
    Rhines, Laurence
    Reynolds, Jeremy
    Laufer, Ilya
    Gasbarrini, Alessandro
    Dea, Nicolas
    Gokaslan, Ziya
    Fisher, Charles
    Bettegowda, Chetan
    Boriani, Stefano
    Hornicek, Francis
    Goodwin, Rory
    Lazary, Aron
    GLOBAL SPINE JOURNAL, 2025, 15 (1_SUPPL) : 120S - 131S
  • [28] Dermatological Toxicity Associated with Targeted Therapies in Cancer: Optimal Management
    Peuvrel, Lucie
    Dreno, Brigitte
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2014, 15 (05) : 425 - 444
  • [29] Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients
    Feliu, J.
    Heredia-Soto, V.
    Girones, R.
    Jimenez-Munarriz, B.
    Saldana, J.
    Guillen-Ponce, C.
    Molina-Garrido, M. J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (04) : 457 - 467
  • [30] Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients
    J. Feliu
    V. Heredia-Soto
    R. Gironés
    B. Jiménez-Munarriz
    J. Saldaña
    C. Guillén-Ponce
    M. J. Molina-Garrido
    Clinical and Translational Oncology, 2020, 22 : 457 - 467